Patient death prompts FDA hold on Mersana’s lead cancer ADC

Patient death prompts FDA hold on Mersana’s lead cancer ADC

Source: 
Fierce Biotech
snippet: 

Another antibody-drug conjugate has been stalled by concerns over safety. The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.